The utility of changes in serum levels of C-terminal telopeptide of type I
collagen in predicting patient response to oral monthly ibandronate therapy.
Author(s): Hochberg MC(1), Silverman SL, Barr CE, Miller PD.
Affiliation(s): Author information:
(1)Division of Rheumatology & Clinical Immunology, Department of Medicine,
University of Maryland School of Medicine, Baltimore, MD 21201, USA.
mhochber@medicine.umaryland.edu
Publication date & source: 2010, J Clin Densitom. , 13(2):181-9
Bone turnover markers may provide a more rapid indication of patient response to
osteoporosis treatment than bone mineral density (BMD) measurements. This post
hoc analysis of data from the MOBILE (Monthly Oral iBandronate In LadiEs) study
assessed the relationship between increases in BMD at 12 mo from baseline after
starting ibandronate treatment and changes in bone resorption marker serum
C-terminal telopeptide of type I collagen (sCTX) from baseline at 3 and 6 mo.
MOBILE enrolled postmenopausal women aged 55-80 yr with mean lumbar spine (LS)
BMD T-score of -2.5 to -5.0. This analysis included women who received 150-mg
monthly oral ibandronate (n=323). A high proportion of women were classified as
BMD responders after 1 yr (BMD increase was >/=0%, i.e., 74-91% depending on
skeletal site; BMD increase was >/=3%, i.e., 34-67%). Women with larger decreases
in sCTX were more likely to be BMD responders. The percent increase in LS BMD at
12 mo was significantly associated with the percent decrease in sCTX at 3 mo from
baseline (Pearson correlation coefficient: -0.19, p=0.0016). In linear regression
models, percent decrease in sCTX at 3 mo from baseline was a significant
predictor of 1-yr LS BMD response (R(2)=0.61, p=0.0007). These data suggest that
3-mo changes in sCTX levels are associated with 1-yr LS BMD increases in
postmenopausal women treated with once-monthly oral ibandronate.
|